gpiib/iiia

Roxifiban acetate(DMP 754 acetate) is a potent GP IIb / IIIa antagonist that exhibits antiplatelet aggregation activity via immune mediation and can be used in the study of human thrombocytopenia.

Elarofiban(RWJ-53308) is a novel and orally active GPIIb/IIIa antagonist.

Tirofiban(MK383) hydrochloride monohydrate is a non-peptide glycoprotein IIb/IIIa antagonist.

MNS is a tyrosine kinases inhibitor, inhibits Syk, Src, p97 with IC50 of 2.5 μM, 29.3 μM and 1.7 μM, respectively.

Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.

GPRP acetate (Pefabloc FG) is fibrinogen-related peptides, which inhibit the interaction of fibrinogen with the platelet membrane glycoprotein IIbIIIa complex (GPIIbIIIa).

Elarofiban TFA (RWJ-53308 TFA) is a novel and orally active and selective GPIIb IIIa antagonist for the study of cardiovascular disease.

Orbofiban, an orally administered antagonist of the platelet GPIIb IIIa receptor, effectively inhibits platelet aggregation.

Orbofiban TFA is an orally active GPIIb IIIa platelet receptor antagonist with inhibitory effects on platelet aggregation for the study of unstable coronary syndromes.

Gantofiban is a glycoprotein IIb IIIa (GP IIb IIIa) antagonist used in the treatment of cardiovascular disease and may be used to study thrombosis.

Roxifiban, a prodrug of XV459, is an antiplatelet agent with high affinity and specificity for platelet glycoprotein IIb/IIIa complex(GPIIb/IIIa) receptors.

YZ-202 is the free acid form of orbofiban. As a class II GPIIb IIIa antagonist, YZ-202 has comparable efficacy to class I antagonists (such as XV459 and DMP802) in inhibiting platelet aggregation, but shows lower potential in altering TF-mediated clot formation strength. This suggests that despite similar anti-aggregation efficacy, YZ-202 may exhibit different effects on platelet-fibrin clot contraction.

EMD 132338 is a GPIIb IIIa antagonist.

PDI-IN-4 (Compound 14d) is a protein disulfide isomerase inhibitor with an IC50 value of 0.48 μM. It prevents platelet aggregation and thrombosis by reducing the activation of GPIIb IIIa, without causing significant cytotoxicity. PDI-IN-4 is applicable in thrombosis research.

Cariporide (HOE-642) (HOE-642), an effective NHE1 inhibitor, has inhibitory effects on the degranulation of human platelets, the formation of platelet-leukocyte-aggregates, and the activation of the GPIIb IIIa receptor (PAC-1).

platelet fibrinogen receptor glycoprotein IIb/IIIa (GpIIb/IIIa) antagonist

Lamifiban trifluoroacetate is an antagonist of the nonpeptide platelet fibrinogen receptor (GPIIb IIIa).

UR-2922 is an oral antagonist of platelet GPIIb/IIIa. UR-2922 possessed a high affinity for the human platelet receptor (K(d) <1 nM) and a slow dissociation rate (k(off)= 90 min) in vitro. UR-2922 induced no ligand-induced binding sites (LIBS) expression

UR-3216, a prodrug, is a selective and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 is the very tight binding of its active metabolite to platelets (Ki for resting platelets is < 1 nM). UR-2992, the active form of

Tirofiban (L700462) (MK-383) is a selective palate GPIIb IIIa antagonist which inhibits platelet aggregation with IC50 of 9 nM.

Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb IIIa complex.

Orbofiban Acetate is a compound that serves as an antagonist to the platelet GPIIb IIIa receptor, effectively inhibiting platelet aggregation when administered orally.

KGDS is a synthetic peptide that targets the integrin GPIIb-IIIa on the membrane of activated human platelets, with the amino acid sequence Lys-Gly-Asp-Ser [1].

Variabilin, a novel inhibitor of human platelet aggregation, it is a potent RGD (Arg-Gly-Asp)-containing antagonist of the fibrinogen receptor glycoprotein IIb-IIIa (GPIIb-IIIa; αIIbβ3) and the vitronectin receptor αvβ3.Variabilin is also an antimicrobial furanosesterterpene. Variabilin is an inhibitor of human secretory and cytosolic phospholipase A2 (PLA2) activities that controls eicosanoid production in vitro and in vivo, inhibits neutrophil degranulation and superoxide generation in vitro and shows anti-inflammatory activity after topical or p.o. administration to mice.